Verastem Stock Price - VSTM

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Verastem Inc VSTM NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.9033 0.00 0.00 0.00 0.9033 08:18:53
Bid Price Ask Price Spread Spread % News
0.88 0.93 0.05 5.38% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Verastem Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 67.16M 74.35M $ -72.43M -1.38 - 72.32M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 2.70%

more financials information »

Verastem News

Loading Messages....

Latest VSTM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VSTM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.101.110.88020.9800161,236,950-0.1967-17.88%
1 Month1.141.380.88021.121,060,132-0.2367-20.76%
3 Months1.351.450.88021.19855,457-0.4467-33.09%
6 Months1.552.050.88021.381,211,010-0.6467-41.72%
1 Year5.455.710.88022.541,836,611-4.55-83.43%
3 Years1.2310.350.88024.391,495,456-0.3267-26.56%
5 Years9.0212.350.88024.371,069,905-8.12-89.99%

Verastem Description

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.


Your Recent History
NASDAQ
VSTM
Verastem
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.